38696-21-8

Basic information

• Product Name: 5-BROMO-2-(DIMETHYLAMINO)PYRIMIDINE
• Synonyms: 5-BROMO-2-(DIMETHYLAMINO)PYRIMIDINE;(5-BROMOPYRIMIDIN-2-YL)DIMETHYLAMINE;5-Bromo-N,N-dimethylpyrimidin-2-amine;2-Pyrimidinamine, 5-bromo-N,N-dimethyl-;2-broMo-N,N-diMethylpyriMidin-4-aMine;5-Bromo-N,N-dimethyl-2-pyrimidinamine;5-Bromo-2-(dimethylamino)pyrimidine 97%
• CAS NO: 38696-21-8
• Molecular Formula: C₆H₈BrN₃
• Molecular Weight: 202.05
• EINECS: 1312995-182-4
• Product Categories: Pyrimidine;Amino;Organohalides;Heterocycle-Pyrimidine series
• Mol File: 38696-21-8.mol

Chemical Properties

• Melting Point: 74-81°C
• Boiling Point: 271.959 °C at 760 mmHg
• Flash Point: 118.277 °C
• Appearance: /
• Density: 1.554 g/cm³
• Vapor Pressure: 0.006mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: 2-8°C(protect from light)
• PKA: 2.21±0.10(Predicted)
• CAS DataBase Reference: 5-BROMO-2-(DIMETHYLAMINO)PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-(DIMETHYLAMINO)PYRIMIDINE(38696-21-8)
• EPA Substance Registry System: 5-BROMO-2-(DIMETHYLAMINO)PYRIMIDINE(38696-21-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36/37
• WGK Germany: 3
• Hazardous Substances Data: 38696-21-8(Hazardous Substances Data)

Usage

Chemical Properties

Off-White crystal

InChI:InChI=1/C6H8BrN3/c1-10(2)6-8-3-5(7)4-9-6/h3-4H,1-2H3

Upstream product

• 5621-02-3 2-(dimethylamino)pyrimidine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 124-40-3 dimethyl amine 
• 506-59-2 N,N-dimethylammonium chloride 
• 32779-36-5 5-Bromo-2-chloropyrimidine 
• 7752-82-1 5-bromo-2-aminopyrimidine 
• 74-88-4 methyl iodide 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 184097-42-5 3-(2-(Dimethylamino)-5-pyrimidyl)aniline 
• 55338-76-6 2-(N,N-Dimethylamino)-5-cyanopyrimidin 
• 1032759-30-0 N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine-2-amine 
• 1351597-83-5 C₁₇H₁₇N₅O₂S 
• 184173-98-6 N-Acetyl 3-(2-(dimethylamino)-5-pyrimidyl)aniline 
• 184174-10-5 N-(3-(2-(Dimethylamino)pyrimid-5-yl)phenyl)-2-amino-4-(1-pyrrolyl)aniline 
• 1581701-33-8 2-(dimethylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide 
• 1083329-56-9 5-N-benzylamino-2-N,N-dimethylaminopyrimidine 
• 56621-99-9 5-amino-2-N,N-dimethylaminopyrimidine 
• 1392405-80-9 N²,N²-dimethyl-N⁵-phenylpyrimidine-2,5-diamine 
• 1362243-15-9 N₅-(4-(dimethylamino)phenyl)-N₂,N₂-dimethylpyrimidine-2,5-diamine 

Relevant articles and documents

INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION

The compounds of Formula I, II, and III along with their stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof are described in the present disclosure. The said compounds restore immune activation in case of infections or a disease associated with an HIV infection in a subject in need thereof.

Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application

Synthesis, temperature-dependent NMR structure investigation and utilization of a new, stable and easily accessible aryl-diadamantylphosphine ligand family is reported. The bulky and electron-rich phosphorus center of the ligand enhances the catalytic activity of palladium in cross-coupling reactions of sterically demanding ortho-substituted aryl halides. In our study, we demonstrated the synthetic applicability of the new phosphine ligands in Buchwald-Hartwig and tosyl hydrazone coupling reactions.

SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS

The present invention relates to LpxC antibacterial compounds of Formula (1A), corresponding pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions:, compound preparation, treatment methods and uses for bacterial infections, especially those caused by gram-negative bacteria.

PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS

The invention relates to new pyridinyl derivatives of the formula (I) wherein R1 and A are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

ANTIOXIDANTS AND METHODS TO MAXIMIZE PERFORMANCE

A method of preventing or reducing the level of degradation of an organic substrate is described, wherein a composition is formed that includes the organic substrate together with an effective amount of a sacrificial base and a diarylamine antioxidant.

ANTI-MALIGNANT TUMOR AGENT COMPOSITION

To provide a satisfactory anticancer agent composition suppressing the growth of cancer (malignant tumor) reliably and hardly causing side effects, the present invention is directed to an anticancer agent composition including the following agents as active ingredient; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

Preparation of highly reactive pyridine- and pyrimidine-containing diarylamine antioxidants

We recently reported a preliminary account of our efforts to develop novel diarylamine radical-trapping antioxidants (Hanthorn, J. J. et al. J. Am. Chem. Soc. 2012, 134, 8306-8309) wherein we demonstrated that the incorporation of ring nitrogens into diphenylamines affords compounds which display a compromise between H-atom transfer reactivity to peroxyl radicals and stability to one-electron oxidation. Herein we provide the details of the synthetic efforts associated with that report, which have been substantially expanded to produce a library of substituted heterocyclic diarylamines that we have used to provide further insight into the structure-reactivity relationships of these compounds as antioxidants (see the accompanying paper, DOI: 10.1021/jo301012x). The diarylamines were prepared in short, modular sequences from 2-aminopyridine and 2-aminopyrimidine wherein aminations of intermediate pyri(mi)dyl bromides and then Pd-catalyzed cross-coupling reactions of the amines and precursor bromides were the key steps to yield the diarylamines. The cross-coupling reactions were found to proceed best with Pd(η3-1-PhC3H 4)(η5-C5H5) as precatalyst, which gave higher yields than the conventional Pd source, Pd2(dba) 3.